Limited and somehow conflicting data have demonstrated that GABA B receptor agonists either promote (e.g., breast [34], kidney [35], and prostate [36] cancers) or inhibit (e.g., lung cancer [37], cholangiocarcinoma [38,39]) the cell growth of nonurothelial malignancies. Here, GABBR1 is linked to lung cancer.